- Home
- AUTL vs TALK Comparison
AUTL vs TALK Comparison
Compare AUTL & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- TALK
- Stock Information
- Founded
- AUTL 2014
- TALK 2012
- Country
- AUTL United Kingdom
- TALK United States
- Employees
- AUTL N/A
- TALK N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- TALK Medical/Nursing Services
- Sector
- AUTL Health Care
- TALK Health Care
- Exchange
- AUTL Nasdaq
- TALK Nasdaq
- Market Cap
- AUTL 590.8M
- TALK 534.6M
- IPO Year
- AUTL 2018
- TALK N/A
- Fundamental
- Price
- AUTL $1.95
- TALK $3.01
- Analyst Decision
- AUTL Strong Buy
- TALK Buy
- Analyst Count
- AUTL 3
- TALK 5
- Target Price
- AUTL $10.20
- TALK $4.38
- AVG Volume (30 Days)
- AUTL 1.2M
- TALK 2.6M
- Earning Date
- AUTL 03-13-2025
- TALK 02-20-2025
- Dividend Yield
- AUTL N/A
- TALK N/A
- EPS Growth
- AUTL N/A
- TALK N/A
- EPS
- AUTL N/A
- TALK 0.01
- Revenue
- AUTL $10,091,000.00
- TALK $187,593,000.00
- Revenue This Year
- AUTL $851.88
- TALK $28.27
- Revenue Next Year
- AUTL $220.57
- TALK $23.44
- P/E Ratio
- AUTL N/A
- TALK $442.17
- Revenue Growth
- AUTL 82.71
- TALK 25.02
- 52 Week Low
- AUTL $1.87
- TALK $1.60
- 52 Week High
- AUTL $6.63
- TALK $4.36
- Technical
- Relative Strength Index (RSI)
- AUTL 37.49
- TALK 36.07
- Support Level
- AUTL $1.92
- TALK $2.94
- Resistance Level
- AUTL $2.15
- TALK $4.36
- Average True Range (ATR)
- AUTL 0.12
- TALK 0.30
- MACD
- AUTL 0.01
- TALK -0.07
- Stochastic Oscillator
- AUTL 22.22
- TALK 5.92
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue primarily stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.